Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T09:32:19.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T23:51:13.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The website has updated the intervention details, now including a verified status and contact information for Guanghai Dai, while removing the previous type of intervention entry.
    Difference
    2%
    Check dated 2025-01-12T18:39:51.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The website has been updated from version v2.13.2 to v2.13.3.
    Difference
    0.1%
    Check dated 2024-12-14T22:51:01.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with a reference to the Contacts and Locations section.
    Difference
    4%
    Check dated 2024-12-07T16:27:59.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The website has added new features, while several menu options and data fields related to study downloads have been removed.
    Difference
    6%
    Check dated 2024-11-23T04:47:17.000Z thumbnail image

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.